# Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

> **NCT03729804** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 250 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT03729804
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-07
- **Primary completion:** 2026-12-28
- **Final completion:** 2026-12-28
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03729804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03729804, "Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03729804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*